Patient-derived orthotopic xenograft models of sarcoma

Sarcoma is a rare and recalcitrant malignancy. Although immune and novel targeted therapies have been tested on many cancer types, few sarcoma patients have had durable responses with such therapy. Doxorubicin and cisplatinum are still first-line chemotherapy after four decades. Our laboratory has e...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2020-01, Vol.469, p.332-339
Main Authors: Igarashi, Kentaro, Kawaguchi, Kei, Murakami, Takashi, Miyake, Kentaro, Kiyuna, Tasuku, Miyake, Masuyo, Hiroshima, Yukihiko, Higuchi, Takashi, Oshiro, Hiromichi, Nelson, Scott D., Dry, Sarah M., Li, Yunfeng, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.
Format: Article
Language:English
Subjects:
Bone cancer
Cancer therapies
Chemotherapy
Colorectal cancer
Doxorubicin
Gene amplification
Histology
Immunosuppressive agents
Implantation
Individualized therapy
Laboratories
Malignancy
Metastasis
Patient-derived sarcoma
Patients
PDOX
Precision medicine
Sarcoma
Surgery
Tumors
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sarcoma is a rare and recalcitrant malignancy. Although immune and novel targeted therapies have been tested on many cancer types, few sarcoma patients have had durable responses with such therapy. Doxorubicin and cisplatinum are still first-line chemotherapy after four decades. Our laboratory has established the patient-derived orthotopic xenograft (PDOX) model using surgical orthotopic implantation (SOI). Many promising results have been obtained using the sarcoma PDOX model for identifying effective approved drugs and experimental therapeutics, as well as combinations of them for individual patients. In this review, we present our laboratory's experience with PDOX models of sarcoma, and the ability of the PDOX models to identify effective approved agents, as well as experimental therapeutics. •Sarcoma is a rare and recalcitrant malignancy.•Present PDOX models of sarcoma.•PDOX models of sarcoma behave quite similar to patient sarcoma.•PDOX models provide sarcoma patients with improved and personalized treatment options.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2019.10.028